| Timing of initiation of antiretroviral drugs during tuberculosis therapy SS Abdool Karim, K Naidoo, A Grobler, N Padayatchi, C Baxter, A Gray, ... New England Journal of Medicine 362 (8), 697-706, 2010 | 921 | 2010 |
| Treatment of highly drug-resistant pulmonary tuberculosis F Conradie, AH Diacon, N Ngubane, P Howell, D Everitt, AM Crook, ... New England Journal of Medicine 382 (10), 893-902, 2020 | 781 | 2020 |
| Integration of antiretroviral therapy with tuberculosis treatment SS Abdool Karim, K Naidoo, A Grobler, N Padayatchi, C Baxter, AL Gray, ... New England Journal of Medicine 365 (16), 1492-1501, 2011 | 648 | 2011 |
| Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection PK Drain, KL Bajema, D Dowdy, K Dheda, K Naidoo, SG Schumacher, ... Clinical microbiology reviews 31 (4), 10.1128/cmr. 00021-18, 2018 | 496 | 2018 |
| HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression … RK Gupta, J Gregson, N Parkin, H Haile-Selassie, A Tanuri, LA Forero, ... The Lancet infectious diseases 18 (3), 346-355, 2018 | 428 | 2018 |
| Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care N Dookie, S Rambaran, N Padayatchi, S Mahomed, K Naidoo Journal of Antimicrobial Chemotherapy 73 (5), 1138-1151, 2018 | 335 | 2018 |
| The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial K Naidoo, N Yende-Zuma, N Padayatchi, K Naidoo, N Jithoo, G Nair, ... Annals of internal medicine 157 (5), 313-324, 2012 | 151 | 2012 |
| Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy V Naranbhai, AVS Hill, SS Abdool Karim, K Naidoo, Q Abdool Karim, ... The Journal of infectious diseases 209 (4), 500-509, 2014 | 143 | 2014 |
| RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response A Penn-Nicholson, SK Mbandi, E Thompson, SC Mendelsohn, S Suliman, ... Scientific reports 10 (1), 8629, 2020 | 115 | 2020 |
| Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial TJ Scriba, A Fiore-Gartland, A Penn-Nicholson, H Mulenga, SK Mbandi, ... The Lancet Infectious Diseases 21 (3), 354-365, 2021 | 114 | 2021 |
| Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research J Dorward, R Lessells, PK Drain, K Naidoo, T de Oliveira, Y Pillay, ... The lancet HIV 5 (7), e400-e404, 2018 | 110 | 2018 |
| HIV, tuberculosis, and noncommunicable diseases: what is known about the costs, effects, and cost-effectiveness of integrated care? EP Hyle, K Naidoo, AE Su, WM El-Sadr, KA Freedberg JAIDS Journal of Acquired Immune Deficiency Syndromes 67, S87-S95, 2014 | 96 | 2014 |
| Long-term adherence to antiretroviral therapy in a South African adult patient cohort: a retrospective study A Moosa, TN Gengiah, L Lewis, K Naidoo BMC infectious diseases 19, 1-12, 2019 | 94 | 2019 |
| Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised … MC Hosseinipour, GP Bisson, S Miyahara, X Sun, A Moses, C Riviere, ... The Lancet 387 (10024), 1198-1209, 2016 | 94 | 2016 |
| Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial PK Drain, J Dorward, LR Violette, J Quame-Amaglo, KK Thomas, ... The lancet HIV 7 (4), e229-e237, 2020 | 91 | 2020 |
| High prevalence of hookah smoking among secondary school students in a disadvantaged community in Johannesburg: scientific letters A Combrink, N Irwin, G Laudin, K Naidoo, S Plagerson, A Mathee South African Medical Journal 100 (5), 297-299, 2010 | 85 | 2010 |
| Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study JM Baeten, T Palanee-Phillips, NM Mgodi, AJ Mayo, DW Szydlo, ... The lancet HIV 8 (2), e87-e95, 2021 | 84 | 2021 |
| Trends in pretreatment HIV-1 drug resistance in antiretroviral therapy-naive adults in South Africa, 2000–2016: a pooled sequence analysis B Chimukangara, RJ Lessells, SY Rhee, J Giandhari, ABM Kharsany, ... EClinicalMedicine 9, 26-34, 2019 | 76 | 2019 |
| Tuberculosis-HIV co-infection: progress and challenges after two decades of global antiretroviral treatment roll-out E Letang, J Ellis, K Naidoo, EC Casas, P Sánchez, R Hassan-Moosa, ... Archivos de bronconeumologia 56 (7), 446-454, 2020 | 75 | 2020 |
| When to start antiretroviral therapy during tuberculosis treatment? K Naidoo, C Baxter, SSA Karim Current opinion in infectious diseases 26 (1), 35-42, 2013 | 75 | 2013 |
